Cooper Stock Price, News & Analysis

BioSkryb Genomics has entered a multi-year partnership with Cooper Genomics to license its high-resolution single-cell genomic amplification technology. This collaboration aims to enhance preimplantation genetic testing (PGT) in reproductive health, addressing infertility that affects 15% of couples globally. The agreement permits Cooper Genomics to market BioSkryb's ResolveDNA^TM technology, which significantly improves testing accuracy and embryo viability assessment, potentially increasing live birth rates and reducing miscarriage and multiple pregnancies.

CooperCompanies (NYSE: COO) has appointed Cynthia Lucchese as an independent director effective October 1, 2022. She will also join the Audit and Corporate Governance Committees. Lucchese brings a wealth of experience as Chief Strategy Officer of Penske Entertainment and has held significant roles at Hulman & Company, Thoratec Corporation, and Hillenbrand. Her extensive financial and strategic expertise is expected to enhance Cooper's board. CooperCompanies operates globally in medical devices with a workforce of approximately 14,000.

CooperVision emphasizes its leadership in myopia control at the upcoming International Myopia Conference in Rotterdam. Highlighting new research on the MiSight® 1 day contact lenses, the company will present findings from a seven-year clinical trial, underscoring its efficacy in myopia management. Senior executives will share insights on various optical interventions tailored for children, including the ortho-k portfolio. This event seeks to educate eye care professionals and raise awareness about myopia control, impacting tens of thousands of children.

CooperCompanies (NYSE: COO) reported fiscal Q3 results for the period ending July 31, 2022. Revenue rose 10% year-over-year to $843.4 million. CooperVision revenue increased 2% to $566.3 million, while CooperSurgical surged 35% to $277.1 million. GAAP diluted earnings per share fell to $1.98, down from $12.37 a year prior. Non-GAAP diluted EPS was $3.19, a decline of 6%. The company expects FY 2022 revenues between $3.29 - $3.31 billion. CEO Al White emphasized strong demand and successful strategic initiatives to enhance shareholder value.

CooperCompanies (NYSE: COO) will participate in the Wells Fargo Healthcare Conference on September 7, 2022, at 1:20 PM ET. President and CEO Al White will represent the company in this session. Interested parties can access a live webcast through the investor relations website. A replay will also be available post-event. Based in San Ramon, California, CooperCompanies operates globally with over 12,000 employees and offers a wide range of products through its divisions, CooperVision and CooperSurgical, serving over 100 countries.

CooperCompanies (NYSE: COO) has appointed Nicholas Khadder as its new general counsel and corporate secretary, effective immediately. Khadder brings extensive legal experience, having previously served as general counsel at Standard BioTools Inc. from June 2016 to July 2022 and held several senior roles at Amyris, Inc. and other companies. He holds a Juris Doctor from Berkeley Law. This leadership change is expected to enhance the company's legal strategy and governance.

CooperCompanies (NYSE: COO) will announce its third quarter 2022 financial results on August 31, 2022, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss the results and other corporate developments. Participants can register for the call through a provided link and listen to a simultaneous webcast available on their website. Cooper, headquartered in San Ramon, CA, operates through CooperVision and CooperSurgical, employing over 12,000 people and selling products in more than 100 countries.

CooperCompanies (NYSE: COO) declared a semi-annual dividend of 3 cents per share, payable on August 11, 2022, to stockholders of record on July 27, 2022. This move aligns with the company’s board-approved strategy to distribute annual dividends. CooperCompanies operates through CooperVision and CooperSurgical, focusing on vision care and women's health products, respectively. The company is headquartered in San Ramon, CA, and employs over 12,000 people globally, with sales in more than 100 countries.

CooperCompanies (NYSE: COO) reported a 15% year-over-year revenue increase to $829.8 million for its fiscal second quarter ending April 30, 2022. CooperVision revenue rose 6% to $553.8 million, while CooperSurgical surged 40% to $276.0 million. GAAP diluted EPS was $2.55, up $0.19, while non-GAAP diluted EPS fell 4% to $3.24. Operating margin decreased to 16% from 20% due to currency effects. The company updated fiscal 2022 revenue guidance to $3,280 - $3,312 million.